Get the Stockscreener App
104.31
3.90%
3.92
After Hours:
104.31
Protagonist Therapeutics Inc stock is traded at $104.31, with a volume of 812.06K.
It is up +3.90% in the last 24 hours and up +19.76% over the past month.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
See More
Previous Close:
$100.39
Open:
$99.42
24h Volume:
812.06K
Relative Volume:
1.01
Market Cap:
$6.66B
Revenue:
$46.02M
Net Income/Loss:
$-130.15M
P/E Ratio:
-51.06
EPS:
-2.0427
Net Cash Flow:
$56.08M
1W Performance:
+7.44%
1M Performance:
+19.76%
6M Performance:
+61.22%
1Y Performance:
+104.33%
1-Day Range:
$97.16
$105.00
1-Week Range:
$97.16
$105.69
52-Week Range:
$39.60
$105.69
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
104.31 | 6.41B | 46.02M | -130.15M | 56.08M | -2.0427 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-12-25 | Initiated | Leerink Partners | Outperform |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) March 2026 - Meyka
US High Growth Tech Stocks to Watch Now - simplywall.st
Highs Report: Is Protagonist Therapeutics Inc forming a bullish divergenceWeekly Stock Report & Intraday High Probability Setup Alerts - baoquankhu1.vn
PTGX (NASDAQ: PTGX) option exercise sale of 54,700 shares - Stock Titan
Protagonist Partners With Johnson & Johnson To Compete With AbbVie's Skyrizi - Seeking Alpha
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $117 - Moomoo
Protagonist Therapeutics stock rallies nearly 7% in a week: Here's why - MSN
Wall Street Says Johnson And Johnson’s FDA-Approved Psoriasis Drug Should Create 'Significant Value’ For Protagonist Therapeutics - Stocktwits
Wall Street says Johnson and Johnson’s FDA-approved psoriasis drug should create 'significant value' for Protagonist Therapeutics - MSN
Protagonist Therapeutics Soars as FDA Approves ICOTYDE for Plaque Psoriasis, Triggers $50M Milestone - MarketBeat
Protagonist Therapeutics (PTGX) soars 4.7%: Is further upside left in the stock? - MSN
(PTGX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Protagonist Therapeutics wins FDA approval for ICOTYDE and joins Fast 500 ranking - Traders Union
Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why - Yahoo Finance
Protagonist Therapeutics (PTGX) Jumps 4.7%: Does the Stock Have More Room to Grow? - Bitget
A Look At Protagonist Therapeutics (PTGX) Valuation After FDA Approval Of ICOTYDE - Yahoo Finance
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock? - Yahoo Finance
PTGX Stock Price, Quote & Chart | PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) - ChartMill
Why Protagonist Therapeutics (PTGX) Is Up 6.6% After First Psoriasis Drug Wins FDA Approval And What's Next - Yahoo Finance
Citigroup Raises Price Target for PTGX to $125, Maintains Buy Ra - GuruFocus
A Look At Protagonist Therapeutics (PTGX) Valuation After ICOTYDE Receives U.S. FDA Approval - simplywall.st
PTGX Analyst Rating Update: Leerink Partners Raises Price Target to $110 | PTGX Stock News - GuruFocus
Protagonist Therapeutics Inc buy JPMorgan Chase & Co. - sharewise.com
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Leerink Partners Analyst Says - MarketBeat
Protagonist Therapeutics (PTGX) Receives Rating Update from JP M - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Given New $106.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 4.6% Following Analyst Upgrade - MarketBeat
Protagonist Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $125.00 at Citigroup - MarketBeat
Johnson & Johnson-Protagonist Therapeutics partnered new psoriasis pill wins FDA nod, shakes up competition with AbbVie - MSN
Protagonist Therapeutics (PTGX) Sees Target Price Upgrade from B - GuruFocus
Protagonist Therapeutics (NASDAQ:PTGX) Given New $119.00 Price Target at Barclays - MarketBeat
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie - Benzinga
Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie - Benzinga
Clear Street raises Protagonist Therapeutics price target on FDA approval By Investing.com - Investing.com Canada
Icotyde’s in; wave of switchers to oral psoriasis Protagonist? - BioWorld MedTech
How an East Bay company picked up $50 million with another $580 million potentially on the way - The Business Journals
Jefferies, Johnson Rice Maintain Buy on Protagonist Therapeutics (PTGX) Mar 2026 - Meyka
Barclays raises Protagonist Therapeutics stock price target on FDA approval By Investing.com - Investing.com Australia
CEO Moves: Is Protagonist Therapeutics Inc stock good for income investorsQuarterly Risk Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Barclays raises Protagonist Therapeutics stock price target on FDA approval - Investing.com
Jefferies raises Protagonist Therapeutics price target on drug approval By Investing.com - Investing.com India
Jefferies raises Protagonist Therapeutics price target on drug approval - Investing.com
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of ICOTYDE for Moderate to Severe Plaque Psoriasis TreatmentSlideshow (NASDAQ:PTGX) 2026-03-18 - Seeking Alpha
Protagonist Therapeutics stock gets Truist buy rating reiterated By Investing.com - Investing.com Canada
FDA clears Protagonist Therapeutics ICOTYDE as first-line oral plaque psoriasis treatment - Traders Union
J&J wins FDA nod for plaque psoriasis pill developed with Protagonist - Seeking Alpha
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis - ACCESS Newswire
FDA approves first oral IL-23 psoriasis pill, Protagonist lands $50M - Stock Titan
Protagonist Therapeutics stock hits all-time high at 98.65 USD By Investing.com - Investing.com South Africa
Protagonist Therapeutics stock hits all-time high at 98.65 USD - Investing.com
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):